Clinical trials: Migraine With Aura
Migraine With Aura
Study of NXN 188 for the Treatment of Migraine With Aura
NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.
- Trial name
- NCT00920686
- Testing
- NXN-188, sumatriptan succinate
- Where
- 16 sites in United States
- Volunteers
- 239 people
- Sponsor
- NeurAxon Inc.
Migraine
Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)
The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a placebo for acute migraine.
- Trial name
- NCT00432237
- Testing
- MK0974 50 mg, MK0974 150 mg, MK0974 300 mg
- Volunteers
- 1,703 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine With Aura
PArtial REbreathing for Migraine With Aura 1
A prospective, multi-centre, randomized, double-blind, sham-controlled, parallel-group, group-sequential study to investigate safety and effectiveness of the Rehaler partial rebreathing device, in adults suffering from migraine…
- Trial name
- PAREMA1 (NCT05546385)
- Testing
- Partial Rebreathing Device
- Where
- 15 sites in United States, Germany
- Volunteers
- 142 people
- Sponsor
- Rehaler
Migraine, With or Without Aura
Safety and Efficacy Study in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
- Trial name
- NCT03235479
- Testing
- Rimegepant
- Where
- 50 sites in United States
- Volunteers
- 1,485 people
- Sponsor
- Pfizer
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s)…
- Trial name
- NCT00382993
- Testing
- Combination Product (sumatriptan succinate/naproxen sodium)
- Where
- 28 sites in United States
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline
Migraine Without Aura, Migraine With Aura
Evaluation of a Novel Device for Treatment of Migraine Headache
Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment.
- Trial name
- NCT03361423
- Testing
- Nerivio Migra-1 active device
- Where
- 12 sites in United States, Israel
- Volunteers
- 296 people
- Sponsor
- Theranica
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Migraine Headache
Efficacy, Tolerability, and Safety of DFN-15
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States
- Trial name
- NCT03009019
- Testing
- DFN-15 Active
- Where
- 43 sites in United States
- Volunteers
- 631 people
- Sponsor
- BioDelivery Sciences International
Migraine, Migraine With Aura
A Study of a Melatonin Receptor Agonist to Prevent Migraine
The purpose of this study is to see if ramelteon will reduce the number of migraine headaches over a 12 week period. The safety and tolerability of ramelteon will also be evaluated. Ramelteon has been approved by the U.S.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT00739024
- Testing
- Ramelteon
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Swedish Medical Center
Migraine Headache, With or Without Aura
Staccato Prochlorperazine in Migraine (in Clinic)
Development of Staccato Prochlorperazine for the treatment of migraine headache.
- Trial name
- NCT00610428
- Testing
- Staccato Prochlorperazine 5 mg, Staccato Prochlorperazine 10 mg
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.
Migraine With or Without Aura
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SPARTAN (NCT02605174)
- Testing
- Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 95 sites in United States
- Volunteers
- 3,005 people
- Sponsor
- Eli Lilly and Company
Migraine, Without Aura
TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)
This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.
- Trial name
- NCT00387881
- Testing
- sumatriptan succinate / naproxen sodium
- Where
- 70 sites in United States
- Volunteers
- 679 people
- Sponsor
- GlaxoSmithKline
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE II (NCT02867709)
- Testing
- Ubrogepant
- Where
- 109 sites in United States
- Volunteers
- 1,686 people
- Sponsor
- Allergan
Migraine, With or Without Aura
Trial in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.
- Trial name
- NCT03461757
- Testing
- Rimegepant
- Where
- 69 sites in United States
- Volunteers
- 1,811 people
- Sponsor
- Pfizer
Migraine Headaches
An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)
A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.
- Trial name
- NCT02856802
- Testing
- Sumatriptan 10 mg Nasal Spray
- Where
- 9 sites in United States
- Volunteers
- 107 people
- Sponsor
- Upsher-Smith Laboratories
Migraine Headache, Aura
Staccato Prochlorperazine in Migraine (Out Patient)
Staccato Prochlorperazine is being developed to treat patients suffering from acute migraine headaches. In October 2005, we completed a 75 patient, multi-center, double-blind placebo-controlled Phase 2A clinical trial in patients…
- Trial name
- NCT00422812
- Testing
- Inhaled PCZ 5 mg, Inhaled PCZ 7.5 mg, Inhaled PCZ 10 mg
- Where
- 25 sites in United States
- Volunteers
- 400 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Migraine Headache
Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine
The study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN Device can reduce the pain and symptoms associated with migraine headaches.
- Trial name
- NCT01462812
- Testing
- Sumatriptan
- Where
- 15 sites in United States
- Volunteers
- 223 people
- Sponsor
- Optinose US Inc.
Migraine With or Without Aura
The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination
The Preventive Treatment of Migraine with Low-Dose Naltrexone and Acetaminophen Combination: A Small, Randomized, Double-Blind, and Placebo-Controlled Clinical Trial with an Open-Label Extension for None-Responders
- Trial name
- NCT03194555
- Testing
- Low-Dose Naltrexone and Acetaminophen Combination
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine, Episodic Migraine
Transnasal Cooling for Migraine
This is a prospective, double-blind, sham-controlled, randomized study to assess the safety, tolerability, and optimal dose of the COOLSTAT Transnasal Thermal Regulating Device for acute treatment of migraine.
- Conditions
- Migraine, Episodic Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT04936061
- Testing
- CoolStat active device
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- CoolTech LLC
Migraine With Aura, Patent Foramen Ovale
Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)
The purpose of the study is to compare the rate of comorbidities associated with migraine aura (MA) between persons who have a large circulatory right-to-left shunt (RLS) and those who do not have RLS.
- Trial name
- CAMP (NCT01257880)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Swedish Medical Center